Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) Invested Capital (2020 - 2026)

GeneDx Holdings has reported Invested Capital over the past 7 years, most recently at $354.1 million for Q1 2026.

  • Quarterly Invested Capital rose 13.19% to $354.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $354.1 million through Mar 2026, up 13.19% year-over-year, with the annual reading at $362.7 million for FY2025, 44.48% up from the prior year.
  • Invested Capital was $354.1 million for Q1 2026 at GeneDx Holdings, down from $362.7 million in the prior quarter.
  • Over five years, Invested Capital peaked at $648.3 million in Q2 2022 and troughed at $234.3 million in Q4 2023.
  • The 5-year median for Invested Capital is $312.9 million (2025), against an average of $334.6 million.
  • Year-over-year, Invested Capital skyrocketed 214.69% in 2022 and then plummeted 54.48% in 2023.
  • A 5-year view of Invested Capital shows it stood at $260.0 million in 2022, then fell by 9.88% to $234.3 million in 2023, then rose by 7.14% to $251.0 million in 2024, then surged by 44.48% to $362.7 million in 2025, then fell by 2.37% to $354.1 million in 2026.
  • Per Business Quant, the three most recent readings for WGS's Invested Capital are $354.1 million (Q1 2026), $362.7 million (Q4 2025), and $347.1 million (Q3 2025).